TheraPPI is a preclinical-stage biotech focused on developing drugs that modify protein–protein interactions to treat oncology, rare diseases, and inflammatory conditions. Its lead program targets the ERK/MyD88 interaction in the Ras-MAPK pathway, an approach the company says dysregulates the pathway rather than blocking it, with the goal of overcoming resistance seen with current Ras-MAPK inhibitors. The company operates through TheraPPI Bioscience SAS (France, founded 2023) and TheraPPI Bioscience SA (Geneva, founded 2024). TheraPPI completed a pre-seed equity financing with backing from PULSALYS, FONGIT and new biotech investors to fund advancement of the ERK/MyD88 program. The company appointed Christopher Meyer, a pharma executive with more than 20 years of international experience, as chairperson of its board to support its next stages of development. No revenue or user metrics were disclosed in the announcement.

Total raised

$0M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Dec 2025